Research & Regulatory News

CagriSema FDA Filing: Where the Review Stands

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Novo Nordisk submitted CagriSema to the FDA in December 2025, supported by the REDEFINE Phase 3 programme. In its report of 4 November 2026, Novo Nordisk said it expected a US decision in the fourth quarter of 2026; none had been announced by 21 November 2026. It would be the first once-weekly fixed combination of a GLP-1 analogue and an amylin analogue for weight management.

Key facts

Filed with FDA
December 2025
Supporting programme
REDEFINE Phase 3
Expected decision
Q4 2026 (Novo Nordisk, 4 November 2026)
PDUFA date
Not publicly confirmed (21 November 2026)
REDEFINE 1
20.4% / 22.7% at 68 weeks
REDEFINE 2
15.7% at 68 weeks (type 2 diabetes)
REDEFINE 4
Non-inferiority vs tirzepatide not met
UK status
No MHRA authorisation

What has been filed

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, an approved GLP-1 receptor agonist, both administered once weekly. Novo Nordisk submitted it to the FDA in December 2025 for chronic weight management. It would be the first once-weekly combination of GLP-1 and amylin analogues to reach the market.

The evidence supporting it

REDEFINE 1, in adults with obesity and without diabetes, reported 20.4% mean weight reduction at 68 weeks across all randomised participants and 22.7% among those who adhered to treatment, against 3.0% and 2.3% on placebo. REDEFINE 2, in adults with type 2 diabetes, reported 15.7% against 3.1% on placebo. The lower figure in the diabetic population is the expected pattern across the entire incretin class rather than a weakness specific to this combination.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What a filing does and does not mean

Submission opens a review; it does not indicate an outcome. The agency assesses the full dossier including manufacturing and long-term safety, and may request additional data. Company guidance about a decision window is a projection, not a commitment by the regulator. As of 21 November 2026, no PDUFA date had been publicly confirmed by either party and Drugs@FDA listed no product containing cagrilintide.

The UK position

An FDA submission has no bearing on UK availability. CagriSema holds no MHRA authorisation, and any UK approval would follow a separate application and assessment, then a separate NICE appraisal before NHS funding. The gap between those steps is typically a year or more, as the orforglipron timeline illustrates.

How it would sit against what exists

If approved, CagriSema's 20.4% would place it above tirzepatide's head-to-head result against semaglutide but below retatrutide's Phase 3 figures. Retatrutide remains investigational with an FDA filing signalled for the first quarter of 2027, so the competitive picture in 2027 would look different from the one a 2026 approval would enter.

Frequently asked questions

When will CagriSema be approved?

It had not been approved as of 21 November 2026. In its report of 4 November 2026, Novo Nordisk said it expected an FDA decision in the fourth quarter of 2026 and was preparing a US launch in early 2027, subject to approval. No PDUFA date has been made public.

Will it be available in the UK?

Not on the basis of an FDA decision. UK availability requires a separate MHRA authorisation, and NHS funding a separate NICE appraisal after that.

Why does REDEFINE 2 report a lower figure?

It enrolled adults with type 2 diabetes, in whom weight reduction is attenuated across the whole incretin class. Comparisons should be made within population.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.